Cargando…

Target SARS-CoV-2: computation of binding energies with drugs of dexamethasone/umifenovir by molecular dynamics using OPLS-AA force field

INTRODUCTION: In recent times, myriads of public have been infected with a novel SARS-CoV-2, and the fatality toll has reached thousands and been mounting step by step, which is a major crisis in the world. The challenge for this burning issue pertinent to repurposed medicines which prevent novel co...

Descripción completa

Detalles Bibliográficos
Autores principales: Nayeem, Sk. Md, Sohail, Ershad Mohammed, Ridhima, G., Reddy, M. Srinivasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791166/
http://dx.doi.org/10.1007/s42600-020-00119-y
_version_ 1783633552053633024
author Nayeem, Sk. Md
Sohail, Ershad Mohammed
Ridhima, G.
Reddy, M. Srinivasa
author_facet Nayeem, Sk. Md
Sohail, Ershad Mohammed
Ridhima, G.
Reddy, M. Srinivasa
author_sort Nayeem, Sk. Md
collection PubMed
description INTRODUCTION: In recent times, myriads of public have been infected with a novel SARS-CoV-2, and the fatality toll has reached thousands and been mounting step by step, which is a major crisis in the world. The challenge for this burning issue pertinent to repurposed medicines which prevent novel coronavirus is of immense concern for all scientists around the globe until the arrival of the vaccine. METHODS: Because of the global high priority rating on the search for the repurposed drugs which outfits clinical suitability to SARS-CoV-2, a unique theoretical methodology is proposed. The approach is based on explorations of biothermodynamics computed via molecular dynamics, root-mean-square deviation (RMSD), radius of gyration (Rg) and interactions. This unique methodology is tested for umifenovir/dexamethasone drugs on (SARS-CoV-2) main protease. RESULTS: This theoretical exploration not only suggested the presence of strong interactions between (SARS-CoV-2 + umifenovir/dexamethasone) but also emphasized the clinical suitability of dexamethasone over umifenovir to treat SARS-CoV-2. This supremacy of dexamethasone is well supported by the results of global clinical trials and COVID-19 therapeutic approved management guidelines of countries. CONCLUSIONS: Thus, this work will pave a way for incremental advancement towards future design and development of more specific inhibitors for the treatment of SARS-CoV-2 infection in humans.
format Online
Article
Text
id pubmed-7791166
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-77911662021-01-08 Target SARS-CoV-2: computation of binding energies with drugs of dexamethasone/umifenovir by molecular dynamics using OPLS-AA force field Nayeem, Sk. Md Sohail, Ershad Mohammed Ridhima, G. Reddy, M. Srinivasa Res. Biomed. Eng. Original Article INTRODUCTION: In recent times, myriads of public have been infected with a novel SARS-CoV-2, and the fatality toll has reached thousands and been mounting step by step, which is a major crisis in the world. The challenge for this burning issue pertinent to repurposed medicines which prevent novel coronavirus is of immense concern for all scientists around the globe until the arrival of the vaccine. METHODS: Because of the global high priority rating on the search for the repurposed drugs which outfits clinical suitability to SARS-CoV-2, a unique theoretical methodology is proposed. The approach is based on explorations of biothermodynamics computed via molecular dynamics, root-mean-square deviation (RMSD), radius of gyration (Rg) and interactions. This unique methodology is tested for umifenovir/dexamethasone drugs on (SARS-CoV-2) main protease. RESULTS: This theoretical exploration not only suggested the presence of strong interactions between (SARS-CoV-2 + umifenovir/dexamethasone) but also emphasized the clinical suitability of dexamethasone over umifenovir to treat SARS-CoV-2. This supremacy of dexamethasone is well supported by the results of global clinical trials and COVID-19 therapeutic approved management guidelines of countries. CONCLUSIONS: Thus, this work will pave a way for incremental advancement towards future design and development of more specific inhibitors for the treatment of SARS-CoV-2 infection in humans. Springer International Publishing 2021-01-08 2022 /pmc/articles/PMC7791166/ http://dx.doi.org/10.1007/s42600-020-00119-y Text en © Sociedade Brasileira de Engenharia Biomedica 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Nayeem, Sk. Md
Sohail, Ershad Mohammed
Ridhima, G.
Reddy, M. Srinivasa
Target SARS-CoV-2: computation of binding energies with drugs of dexamethasone/umifenovir by molecular dynamics using OPLS-AA force field
title Target SARS-CoV-2: computation of binding energies with drugs of dexamethasone/umifenovir by molecular dynamics using OPLS-AA force field
title_full Target SARS-CoV-2: computation of binding energies with drugs of dexamethasone/umifenovir by molecular dynamics using OPLS-AA force field
title_fullStr Target SARS-CoV-2: computation of binding energies with drugs of dexamethasone/umifenovir by molecular dynamics using OPLS-AA force field
title_full_unstemmed Target SARS-CoV-2: computation of binding energies with drugs of dexamethasone/umifenovir by molecular dynamics using OPLS-AA force field
title_short Target SARS-CoV-2: computation of binding energies with drugs of dexamethasone/umifenovir by molecular dynamics using OPLS-AA force field
title_sort target sars-cov-2: computation of binding energies with drugs of dexamethasone/umifenovir by molecular dynamics using opls-aa force field
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791166/
http://dx.doi.org/10.1007/s42600-020-00119-y
work_keys_str_mv AT nayeemskmd targetsarscov2computationofbindingenergieswithdrugsofdexamethasoneumifenovirbymoleculardynamicsusingoplsaaforcefield
AT sohailershadmohammed targetsarscov2computationofbindingenergieswithdrugsofdexamethasoneumifenovirbymoleculardynamicsusingoplsaaforcefield
AT ridhimag targetsarscov2computationofbindingenergieswithdrugsofdexamethasoneumifenovirbymoleculardynamicsusingoplsaaforcefield
AT reddymsrinivasa targetsarscov2computationofbindingenergieswithdrugsofdexamethasoneumifenovirbymoleculardynamicsusingoplsaaforcefield